Results 11 to 20 of about 1,953 (104)

Bispecific antibodies with Fab-arms featuring exchanged antigen-binding constant domains

open access: yesBiochemistry and Biophysics Reports, 2021
Monoclonal antibodies can acquire the property of engagement of a second antigen via fusion methods or modification of their CDR loops, but also by modification of their constant domains, such as in the mAb2 format where a set of mutated amino acid ...
Filippo Benedetti   +5 more
doaj   +1 more source

Preparation of monovalent follistatin-like 3-Fc-fusion protein and evaluation of its effects on muscle mass in mice

open access: yesSTAR Protocols, 2021
Summary: Follistatin-like 3 (FSTL3) is an endogenous antagonist against transforming growth factor-β family ligands. Monovalent FSTL3-Fc fusion protein (mono-FSTL3-Fc) generated with knobs-into-holes technology overcomes limitations of current anti ...
Takayuki Ozawa   +2 more
doaj   +1 more source

Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain. [PDF]

open access: yesPLoS ONE, 2013
Bispecific antibodies are considered as a promising class of future biotherapeutic molecules. They comprise binding specificities for two different antigens, which may provide additive or synergistic modes of action.
Sebastian Fenn   +12 more
doaj   +1 more source

An integrated approach for characterizing immunogenic responses toward a bispecific antibody

open access: yesmAbs, 2021
Bispecific antibodies (bsAbs) recognize and bind two different targets or two epitopes of the same antigen, making them an attractive diagnostic and treatment modality.
Sivan Cohen   +14 more
doaj   +1 more source

Systemic administration of monovalent follistatin-like 3-Fc-fusion protein increases muscle mass in mice

open access: yesiScience, 2021
Summary: Targeting the signaling pathway of growth differentiation factor 8 (GDF8), also known as myostatin, has been regarded as a promising strategy to increase muscle mass in the elderly and in patients.
Takayuki Ozawa   +7 more
doaj   +1 more source

Ebola and Marburg virus VP35 coiled-coil validated as antiviral target by tripartite split-GFP complementation

open access: yesiScience, 2022
Summary: Ebola virus (EBOV) and Marburg virus (MARV) are highly pathogenic viruses in humans, against which approved antivirals are lacking. During EBOV and MARV infection, coiled-coil mediated oligomerization is essential for the virion protein 35 (VP35)
Luca Zinzula   +6 more
doaj   +1 more source

IMGT® Nomenclature of Engineered IGHG Variants Involved in Antibody Effector Properties and Formats

open access: yesAntibodies, 2022
The constant region of the immunoglobulin (IG) or antibody heavy gamma chain is frequently engineered to modify the effector properties of the therapeutic monoclonal antibodies.
Marie-Paule Lefranc, Gérard Lefranc
doaj   +1 more source

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

open access: yesJournal of Experimental & Clinical Cancer Research, 2019
Background Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancers, which is associated with poor prognosis. Herceptin and other agents targeting HER2 have potent antitumor efficacy in patients with HER2-positive cancers ...
Shengnan Yu   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy